Large molecule manufacturing: addressing challenges with strategies for success
Discover the landscape of large molecule manufacturing, exploring challenges, latest innovations, and winning strategies for success.
Antibodies
- Latest Posts
Best in Biotech 7 Mar 2024
6 biotech companies tackling antibiotic resistance
Discover six antibiotic companies developing novel therapies in an attempt to overcome the global issue of antibiotic resistance.
How to select the right CDMO for innovative antibody development
News and Trends 20 Jun 2023
Clearance for anti-tumor bispecific antibody trial
TG ImmunoPharma Co., Ltd. (TGI), which focuses on the development of novel immuno-oncology therapies, says the FDA has granted clearance for the clinical trial of TGI-6, its bispecific antibody. TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling potent anti-tumor responses. TGI said the antibody demonstrates exceptional anti-tumor activity, favorable safety profiles, and […]
News and Trends 16 May 2023
LabGenius looks to create molecules with huge increase in tumor killing ability
LabGenius, which uses machine learning (ML) for antibody discovery, has presented data in a poster presentation at the Protein Engineering and Biotherapeutics (PEGS) annual meeting. The data were from LabGenius’ T-cell engager (TCE) lead optimization platform, which delivered highly potent and efficacious single-domain antibodies with best-in-class killing selectivity. Optimizing antibody therapeutics across multiple properties is […]
News and Trends 2 May 2023
FDA fast track for Memo’s kidney transplant infection treatment
Memo Therapeutics AG, a biotech company developing therapeutic antibodies, says the U.S. Food and Drug Administration (FDA) has granted fast track designation to AntiBKV, Memo Therapeutics’ lead antibody therapeutic that targets BK polyomavirus (BKV) infection commonly seen in renal transplant patients. AntiBKV has successfully completed a phase I clinical study and following FDA clearance has […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 8 Mar 2023
Affibody and Chiesi Group to develop treatments for respiratory diseases
Affibody AB and Chiesi Farmaceutici S.p.A have announced a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using Affibody’s proprietary technology. Under the terms of the agreement, the parties will collaborate to progress up to three programs based on Affibody molecules against undisclosed targets for respiratory diseases. Chiesi will fund […]
News and Trends 2 Mar 2023
Antiverse identifies therapeutic antibodies targeting GPCRs
Antiverse Ltd has announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors (GPCRs), both displaying versatile binding profiles and nanomolar affinity. Antiverse, which was featured as one of our five Welsh biotech startups making waves in 2023, also announced it has raised $3 million funding, which will enable in-house development of the […]
News and Trends 21 Feb 2023
Hemab Therapeutics receives $135M to address bleeding and thrombotic disorders
Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, has announced the closing of an oversubscribed $135 million Series B financing. Access Biotechnology led the round, with participation from new investors Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity, as well […]
News and Trends 10 Feb 2023
FDA approves GSK drug for recurrent or advanced mismatch repair-deficient endometrial cancer
GSK plc says the US Food and Drug Administration (FDA) has given full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a US FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not […]
News and Trends 7 Feb 2023
Antibody candidate for treating serious liver disease
There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people with type 2 diabetes and which can result in other serious liver diseases. However, a new study led by researchers from Karolinska Institutet in Sweden has identified a drug candidate for the treatment of fatty liver. The preclinical study, published […]
News and Trends 18 Jan 2023
BioInvent receives funding for blood cancer treatments
BioInvent International AB has been selected as partner of The Leukemia & Lymphoma Society’s Therapy Acceleration Program (LLS TAP). The program is aimed at advancing the company’s program to treat blood cancers. The partnership will include access to the scientific, clinical and drug development expertise of LLS as well as a strategic capital equity investment […]
ADVERTISEMENT
